The ASCP Annual Meeting is the premier meeting each year in the field of psychopharmacology. Bringing together representatives from academia, the National Institutes of Health (NIH), Food and Drug Administration (FDA), European regulatory agencies, and industry to discuss key aspects of neuropsychiatric drug development, including the impact of diagnostic changes and personalized interventions based on biomarkers or genetic information. A Program Committee for the Annual Meeting chaired by Drs. Tiffany Farchione and Carlos Blanco including representatives from the ASCP Community, FDA, EMA, NIMH, NIDA, NIAAA, and the academia members, lead the direction of the meeting. The Review Subcommittee, under the leadership of Drs. Manish Jha and Dan Iosifescu, are responsible for the review of all program submissions. To ensure the meeting includes the needs of our loyal pharmaceutical industry members, we are excited to announce the launch of the ASCP Industry Advisory Council led by Drs. Ross Baker and Julie Adams.

The ASCP Annual Meeting brings together over 900 academic and industry investigators, research pharmacists, and clinicians, including competitively selected New Investigator Awardees. ASCP is joined by federal partners, the National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism, (NIAAA) and the Food and Drug Administration (FDA) to organize a program that emphasizes the presentation of information that has not been previously published or presented.

In recent years, the ASCP Annual Meeting focus has been expanded to address a number of timely issues relevant to clinical research in psychiatry, including the translation of research into practice, the importance of regulatory issues, and pharmacogenetics and other means to personalizing interventions.

Registration for the 2026 Annual Meeting will open in December 2025.